Syngene International, a global contract research, development and manufacturing organisation (CRDMO), announced on Monday that it is adding a GMP bioconjugation suite at its commercial biologics facility (Unit 3) in Bengaluru, India.

With this new capability, Syngene will offer fully integrated, end-to-end services for antibody-drug conjugates (ADCs) from discovery through to GMP manufacturing.

The OEB-5 rated suite is intended to accelerate ADC development timelines by allowing both Monoclonal Antibodies (mAb) production and GMP bioconjugation at a single site, complementing Syngene's existing commercial capabilities in payload and linker manufacturing.

Expected to be operational within the current financial year, the conjugation facility will also support a range of advanced conjugates and related modalities.